TYRA-300 - (SURF302)

August 4, 2026: Tyra Biosciences (NASDAQ: TYRA) reported pipeline updates for oral FGFR3-selective inhibitor dabogratinib and Q2 2026 financials. In Phase 2 SURF302 in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, the company said it will report initial results in September 2026, including safety from more than 40 patients and efficacy from more than 20 patients across the 50 mg and 60 mg once-daily cohorts.

For Phase 2a/b SURF303 in low-grade upper tract urothelial carcinoma, evaluating 60 mg and 80 mg once daily, initial results remain expected in 2027.

For Phase 2 BEACH301 in children ages 3-10 with achondroplasia, the safety sentinel cohort has cleared four dose levels with no notable safety events reported to date; a Data Safety Monitoring Committee authorized a fifth dose level of 0.625 mg/kg. Initial safety sentinel data, including 6-month annualized height velocity and safety across dose levels 1-5 in about 25 children, are now expected at the end of Q1 2027.

The company also appointed Jonathan Day as EVP, Clinical Development in June 2026 to lead dabogratinib development in skeletal dysplasia conditions. Cash, cash equivalents, and marketable securities were $353.9 million as of June 30, 2026, with runway projected into 2H 2028.